Teleflex (NYSE:TFX) Upgraded to Outperform at Raymond James Financial

Raymond James Financial upgraded shares of Teleflex (NYSE:TFX) from a market perform rating to an outperform rating in a research note published on Friday, Marketbeat Ratings reports. Raymond James Financial currently has $128.00 price target on the medical technology company’s stock.

Other analysts have also recently issued research reports about the company. Zacks Research cut Teleflex from a “hold” rating to a “strong sell” rating in a research report on Monday, March 2nd. Wall Street Zen cut Teleflex from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Wells Fargo & Company raised their price target on Teleflex from $116.00 to $130.00 and gave the stock an “equal weight” rating in a report on Friday, February 27th. Weiss Ratings restated a “sell (d)” rating on shares of Teleflex in a research note on Monday, December 29th. Finally, Royal Bank Of Canada upped their price objective on shares of Teleflex from $115.00 to $125.00 and gave the company a “sector perform” rating in a report on Friday, February 27th. Three analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $139.00.

Teleflex Stock Up 5.2%

Shares of NYSE TFX opened at $116.23 on Friday. Teleflex has a 12-month low of $100.18 and a 12-month high of $141.91. The stock’s fifty day simple moving average is $109.07 and its two-hundred day simple moving average is $116.76. The stock has a market capitalization of $5.14 billion, a PE ratio of -5.66, a price-to-earnings-growth ratio of 0.69 and a beta of 0.87. The company has a current ratio of 2.54, a quick ratio of 2.01 and a debt-to-equity ratio of 0.81.

Teleflex (NYSE:TFX) last issued its quarterly earnings data on Thursday, February 26th. The medical technology company reported $1.93 earnings per share for the quarter, missing analysts’ consensus estimates of $3.73 by ($1.80). Teleflex had a positive return on equity of 14.30% and a negative net margin of 30.56%.The company had revenue of $569.00 million for the quarter, compared to analysts’ expectations of $912.57 million. During the same quarter last year, the company earned $3.89 earnings per share. The company’s revenue for the quarter was down 28.5% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. As a group, analysts expect that Teleflex will post 13.98 EPS for the current fiscal year.

Teleflex Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Friday, March 6th will be paid a $0.34 dividend. The ex-dividend date is Friday, March 6th. This represents a $1.36 dividend on an annualized basis and a yield of 1.2%. Teleflex’s dividend payout ratio (DPR) is -6.62%.

Institutional Trading of Teleflex

Several large investors have recently added to or reduced their stakes in TFX. Janus Henderson Group PLC lifted its holdings in shares of Teleflex by 2.0% during the fourth quarter. Janus Henderson Group PLC now owns 4,246,112 shares of the medical technology company’s stock worth $518,196,000 after purchasing an additional 84,754 shares during the period. AQR Capital Management LLC raised its holdings in shares of Teleflex by 478.1% during the third quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company’s stock worth $287,603,000 after purchasing an additional 1,956,811 shares during the last quarter. State Street Corp raised its holdings in shares of Teleflex by 1.5% during the fourth quarter. State Street Corp now owns 1,478,776 shares of the medical technology company’s stock worth $180,470,000 after purchasing an additional 22,111 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Teleflex by 0.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,250,665 shares of the medical technology company’s stock valued at $152,630,000 after purchasing an additional 5,051 shares during the period. Finally, Cooke & Bieler LP boosted its holdings in Teleflex by 1.2% in the third quarter. Cooke & Bieler LP now owns 1,220,637 shares of the medical technology company’s stock valued at $149,357,000 after purchasing an additional 14,673 shares during the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Key Stories Impacting Teleflex

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Irenic, a ~2% Teleflex shareholder, called for the Board to form a strategic-review sub‑committee with independent directors and to engage potential acquirers — a direct catalyst for takeover interest that can lift valuation expectations. Irenic Comments on Teleflex’s Announcement That It Is Open to Strategic Alternatives
• Positive Sentiment: Raymond James upgraded Teleflex from Market Perform to Outperform with a $128 price target, signaling analyst conviction that there’s upside from either operational improvement or strategic outcomes. Raymond James upgrade coverage
• Neutral Sentiment: Teleflex issued a formal statement reiterating its commitment to value‑maximizing strategies and said management met with Irenic on March 19 to understand their views — indicates engagement but not yet a formal review process. Teleflex Reiterates Commitment to Value‑Maximizing Strategies and Strong Execution
• Neutral Sentiment: Other shareholders and outlets are echoing calls for Teleflex to engage potential buyers, adding public pressure that could push the Board toward a more formal process. Teleflex shareholder urges company engage buyers
• Negative Sentiment: Teleflex pushed back, saying Irenic falsely claimed the company was not open to buyout offers — the public dispute raises governance/uncertainty risk and could deter some bidders or prolong a process. Teleflex says Irenic falsely claimed company was not open for buyout offers
• Negative Sentiment: Fundamentals remain a headwind: Teleflex reported a large recent earnings and revenue miss and guidance that reflects recovery needs — operational weakness could limit strategic options or depress standalone valuation until results improve.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.